Volatile biomarker for predicting AD (Alzheimer's disease) development as well as screening method and application of volatile biomarker

CN118914534APending Publication Date: 2024-11-08SHAANXI UNIV OF SCI & TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411145700.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

[0004]本发明的目的在于提供一种预测AD发展的挥发性生物标志物及其筛选方法和应用,用以解决现有的确定方法需要通过有创的方式进行的技术问题

Benefits of technology

[0024] The invention discloses a volatile biomarker for predicting the development of AD, which can provide a new method for early diagnosis and monitoring of the disease, and realize diagnosis, screening, prognosis and monitoring of the disease in a non-invasive manner.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005002125500000111
    Figure BDA0005002125500000111
  • Figure BDA0005002125500000121
    Figure BDA0005002125500000121
  • Figure HDA0005002125510000011
    Figure HDA0005002125510000011
Patent Text Reader

Abstract

The invention discloses a volatile biomarker for predicting AD development and a screening method and application thereof, and belongs to the technical field of biological medicine. The volatile biomarker for predicting AD development disclosed by the invention can provide a new method for early diagnosis and monitoring of diseases, diagnosis, screening, after-healing and monitoring of the diseases are realized in a noninvasive manner, and the method is reliable in result, simple in implementation process and wide in application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a volatile biomarker for predicting the development of AD and a screening method and application thereof. Background Art

[0002] As the problem of global population aging becomes increasingly serious, exploring effective dietary intervention strategies to alleviate cognitive impairment caused by age-related neurodegenerative diseases such as Alzheimer's disease (AD) has important public health significance. Studies have shown that food-borne ergothioneine (ET) can penetrate the blood-brain barrier and has the ability to regulate the oxidative stress response of the central nervous system, and is highly safe and stable in the human body. The level of ET in plasma decreases with age, and dietary supplementation of ET can be an effective strategy to alleviate AD-related cognitive impairment.

[0003] Short-chain fatty acids (SCFAs) are the main metabolites produced by colonic bacteria and play a key role in regulating neuroimmunoendocrine, metabolic homeostasis, infection and inflammatory functions. The levels of SCFAs and the abundance of SCFA-producing bacterial species are reduced in patients with mild cognitive impairment and AD. In addition, the reduction of SCFA levels in the feces of MCI patients is negatively correlated with Aβ deposition. As a key regulator of intestinal health, SCFAs not only provide energy for intestinal cells, but also regulate immune responses and intestinal barrier function, and have potential effects on the health of the central nervous system. Volatile Organic Compounds (VOCs) are a class of organic compounds that have a high vapor pressure and are easily volatile at room temperature. By detecting VOCs in breath, saliva, blood, skin secretions, urine and feces, it is possible to provide important information about the health status of the human body. Gas Chromatography-Ion Mobility Spectrometry (GC-IMS) is an important technology in the analysis of volatile organic compounds. This technology combines the advantages of gas chromatography and ion mobility spectrometry. GC is used to separate various compounds in complex samples, while IMS is used to detect and identify the ions of these compounds, thereby achieving rapid identification and quantification of compounds. Studies on VOCs in the feces of early and mid-stage AD patients and healthy people found that the content of heptanoic acid increased with the progression of AD and can be used as a potential biomarker for the onset and progression of AD. In addition, the feces of AD patients contain more acids and esters, while the feces of healthy subjects contain more terpenes, sulfur compounds and aldehydes. Volatile omics can provide new methods for the early diagnosis and monitoring of diseases, and achieve diagnosis, screening, recovery and monitoring of diseases in a non-invasive way. At present, there are no reports on the study of VOCs in the feces of APP / PS1 mice. Summary of the invention

[0004] The purpose of the present invention is to provide a volatile biomarker for predicting the development of AD and a screening method and application thereof, so as to solve the technical problem that the existing determination method needs to be carried out in an invasive manner.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions:

[0006] The present invention discloses a volatile biomarker for predicting the development of AD, comprising one or more of 3-methylvaleric acid, 4-methylvaleric acid, propyl acetate, 1-penten-3-ol, 2,3-pentanedione, 3-methyl-2-butenal-D, hexanal-D, 2-ethoxyethanol, hexanal, 1-butanol, 2-methylbutanal, ethyl acetate and 2-acetone, propionic acid, isobutyric acid, butyric acid, valeric acid and isovaleric acid.

[0007] Further, 3-methylvaleric acid, 4-methylvaleric acid, propyl acetate-D and propyl acetate are included.

[0008] Further, isobutyric acid, butyric acid, valeric acid and 2-methylbutyric acid are included.

[0009] Furthermore, it includes propyl acetate, 1-penten-3-ol, 2,3-pentanedione, and 3-methyl-2-butenal-D.

[0010] The present invention also discloses a method for determining the above-mentioned volatile biomarker combination for predicting the development of AD, comprising the following steps:

[0011] The mice were intervened with ergothioneine diet to obtain different mouse groups. The feces of the different mouse groups were tested for short-chain fatty acids and volatile components using the GC-IMS test method to obtain the GC-IMS data of volatile components in the feces of the different mouse groups.

[0012] The GC-IMS data of fecal volatile components were analyzed to obtain volatile biomarkers.

[0013] Furthermore, the analysis of the GC-IMS data of fecal volatile components includes the following steps:

[0014] S1: Collect behavioral data of mice in different groups, and perform correlation analysis between behavioral data of mice in different groups and GC-IMS data of fecal volatile components, establish a mouse model of AD disease symptoms, and obtain volatile biomarkers that are positively correlated with the behavioral data of AD group mice through the mouse model of AD disease symptoms;

[0015] S2: Select the characteristic peak position points of the ion mobility spectrum in the spectrum of the GC-IMS data, and determine the corresponding volatile organic compounds as candidate volatile biomarkers;

[0016] S3: Draw the fingerprint spectrum of volatile organic compounds, compare the differences and changes of volatile organic compounds between different groups of mice based on the fingerprint spectrum, and screen and determine the volatile organic compounds;

[0017] S4: Draw a cluster heat map of the feces of different groups of mice, analyze the principal components of the feces of different groups of mice, obtain different clustering situations of volatile biomarkers with positive correlation and volatile organic compounds determined by screening, and perform difference and similarity analysis of volatile biomarkers based on the clustering situation.

[0018] Furthermore, the types of the different groups of mice include AD group mice, AD-LET group mice, AD-HET group mice or C57BL / 6 group mice.

[0019] Furthermore, the behavioral data include the total movement distance in the open field movement test, the alternation success rate in the Y maze test, and the exploration time in the novel object recognition test.

[0020] Furthermore, the process of establishing the mouse model of AD disease symptoms specifically includes the following steps:

[0021] Behavioral data of mice in different groups were collected, the correlation between volatile biomarkers in feces and the age of mice in different groups was analyzed, the changes in metabolic pathways of mice in different groups were observed, and the relationship between the age of mice in different groups and their total movement distance in the open field movement test, the alternation success rate in the Y maze test, and the exploration time in the novel object recognition test was studied to establish a mouse model of AD disease symptoms.

[0022] The present invention also discloses the application of the above-mentioned volatile biomarker combination for predicting the development of AD in predicting the development of AD.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The present invention discloses a volatile biomarker for predicting the development of AD, which can provide a new method for early diagnosis and monitoring of the disease, and realize the diagnosis, screening, recovery and monitoring of the disease in a non-invasive manner.

[0025] The present invention also discloses a method for determining the above-mentioned combination of volatile biomarkers for predicting the development of AD. Mice are intervened with an ergothioneine diet, and the effect of ET dietary intervention on SCFAs in the feces of APP / PS1 mice is studied based on fecal samples of different mouse groups, so as to obtain specific volatile components as early AD monitoring markers. The method has reliable results, simple implementation process, and broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is a cluster heat map analysis of short-chain fatty acids in mouse feces;

[0027] Figure 2 The figure shows the content of short-chain fatty acids in mouse feces;

[0028] Figure 3 The ion mobility spectra of volatiles in fecal samples of different mouse groups;

[0029] Figure 4 The fingerprints of volatile components of fecal samples from different mouse groups;

[0030] Figure 5 This is the cluster heat map of mouse fecal samples;

[0031] Figure 6 This is a correlation analysis chart of the behavioral data of AD group mice and their fecal volatiles. DETAILED DESCRIPTION

[0032] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.

[0033] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.

[0034] Herein, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are for simplicity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values ​​within the range (including integers and fractions).

[0035] In this document, unless otherwise specified, “includes,” “including,” “contains,” “has,” or similar terms cover the meanings of “consisting of” and “mainly consisting of,” for example, “A includes a” covers the meanings of “A includes a and other” and “A only includes a.”

[0036] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.

[0037] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0038] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The various raw materials used in the following examples are conventional commercial products unless otherwise specified, and their specifications are conventional specifications in the art. In the specification of the present invention and the following examples, unless otherwise specified, "%" means weight percentage, "part" means weight part, and ratio means weight ratio.

[0039] A volatile biomarker for predicting the development of AD in AD group mice, the key markers include: 3-methylvaleric acid, 4-methylvaleric acid, propyl acetate-D, propyl acetate;

[0040] The above-mentioned method for screening volatile biomarkers for predicting the development of AD comprises the following steps:

[0041] S1: Feces of mice in the AD group were collected, subjected to low-temperature shaking, crushing, ice bath, ultrasound, mixing and centrifugation, and derivatized with pyridine, EDC solution and 3-NPH for LC-MS / MS analysis.

[0042] S2: The volatile organic compounds in the feces of mice in the AD group were measured using GC-IMS technology to obtain the GC-IMS data of the volatile component samples of the feces of mice in the AD group;

[0043] S3: Data analysis: GC-IMS data of fecal volatile components of AD mice were analyzed to obtain volatile biomarkers for predicting the development of AD, including the following steps:

[0044] S31: PCoA analysis was performed on the GC-IMS data of fecal volatile component samples of AD mice, and the grouping trend of feces distribution in different mouse groups on the PCoA graph was obtained: AD mice were distributed farther on the PCo1 axis than WT mice, indicating that the SCFAs composition of AD mice was significantly different from that of WT mice; compared with the WT group, the acetic acid content in the feces of AD mice tended to decrease, while the contents of propionic acid, isobutyric acid, butyric acid, valeric acid, isovaleric acid and 2-methylbutyric acid were significantly reduced (p<0.05), such as Figure 2As shown in the figure, the distribution of PCoA in samples from different mouse groups showed obvious grouping trends, the reasons for significant differences among different mouse groups were compared, SCFAs in mouse fecal samples were detected, the main SCFAs were analyzed, and the SCFAs content of different mouse groups after ET diet intervention was compared;

[0045] S32: Based on the GC-IMS data of fecal volatile component samples of AD group mice, feature points were selected and searched by GC-IMS to obtain GC-IMS spectra, and the GC-IMS spectra were observed to compare and analyze the differences in volatile organic compound concentrations in different groups;

[0046] S33: The behavioral data of AD mice were used for correlation analysis with volatile substances, and the correlation between volatile substances in feces and the age of AD mice was analyzed. The changes in the metabolic pathways of mice were observed, and the relationship between the age of mice and their total movement distance in the open field movement test, the alternation success rate in the Y maze test, and the exploration time in the new object recognition test was studied. A mouse model of AD disease symptoms was established, and VOCs in the feces of 3-month-old, 6-month-old and 9-month-old AD mice were detected. By analyzing the correlation between the age of mice and behavioral data, the study found that some specific VOCs were significantly positively or negatively correlated with the age of mice; hexanal, 1-butanol and 2-methylbutanal were significantly positively correlated with the age of AD mice (R2≥0.88), while the contents of ethyl acetate and 2-acetone showed a significant negative correlation (R2=-0.76 and R2=-0.73, respectively), such as Figure 6 As shown;

[0047] S34: Determine candidate molecular markers: Select characteristic peak positions of ion mobility spectra in the GC-IMS spectrum and determine corresponding volatile organic compounds as candidate mouse volatile substance markers, such as Figure 3 As shown;

[0048] S35: Comparison of changes in molecular markers in each group: The fingerprint spectrum of volatile substances was drawn, and the volatile organic compounds corresponding to the characteristic peaks of the migration spectrum were selected in the VOC fingerprint spectrum. In the feces of the AD group mice, the contents of ethylpropanoate-D, ethylpropanoate, 1-penten-3-ol, 2,3-pentadione, 3-methyl-2-butenal, 3-hydroxy-2-butanone, propanal, formic acid, 1-propanol and other substances were relatively high. However, with the increase of the age of the AD group mice, the contents of these substances in the feces of the 9-month-old AD group mice were significantly reduced. On the other hand, the contents of 3-Methyl-2-butenal-D, hexanal-D, 2-ethoxy-Ethanol, 3-Methyl-3-buten-1-ol, hexanal, pentanal, 3-methylbutanal-D, 2-methylbutanal, 1-butanol, benzaldehyde-D, benzaldehyde, 2-ethyl-5-methylpyrazine and other substances in the feces of 9-month-old AD mice were significantly higher, showing the potential as AD diagnosis and treatment markers; the differences in volatile organic compound content between different samples were compared to explore the reasons for the changes in volatile organic compounds, and the changes in molecular markers in each group were compared to screen comparative samples;

[0049] S36: Comparison of differences and similarities between different markers: Plotting cluster heat maps of mouse fecal samples and analyzing the principal components of mouse fecal samples. Cluster analysis of volatile organic compounds was performed to visually compare the differences and similarities between different compounds. In the PCoA graph, the closer the distance between the sample points, the more similar their VOCs compositions. On the contrary, points that are farther apart indicate that they have greater differences in compound composition. The VOCs composition of WT mice was significantly different from that of AD mice and ET-treated mice; as AD mice age, changes in the composition of VOCs may be related to metabolic changes associated with disease progression, such as Figure 5 shown.

[0050] Example 2

[0051] A panel of volatile biomarkers predicting the development of AD in AD-LET mice, including isobutyrate, butyrate, valeric acid, and 2-methylbutyrate;

[0052] The above-mentioned method for screening volatile biomarkers for predicting the development of AD comprises the following steps:

[0053] S1: Feces of mice in the AD-LET group were collected and subjected to low-temperature shaking, crushing, ice bath, ultrasound, mixing and centrifugation. Pyridine, EDC solution and 3-NPH were added for derivatization and then used for LC-MS / MS detection and analysis;

[0054] S2: The volatile organic compounds in the feces of the AD-LET group mice were measured using GC-IMS technology to obtain the GC-IMS data of fecal volatile components;

[0055] S3: Analyze the GC-IMS data of fecal volatile components to obtain volatile biomarkers, which specifically includes the following processes:

[0056] S31: PCoA analysis of the data in mouse feces showed that there was an obvious grouping trend in the distribution of PCoA samples from different mouse groups. The distribution of AD-LET mice on the PCo1 axis was closer to that of WT mice, indicating that low-dose ET intervention had a positive effect on the SCFAs composition of AD mice. A total of 11 SCFAs were detected in the fecal samples of the four groups of mice; acetic acid, propionic acid and butyric acid were the main SCFAs, see Figure 1 ; The composition of short-chain fatty acids in the feces of mice in the AD-LET group was highly similar to that of the WT group and clustered together; The contents of SCFAs in the feces of the four groups of mice were compared with those of the WT group. The content of acetic acid in the feces of mice in the AD group showed a downward trend, while the contents of propionic acid, isobutyric acid, butyric acid, valeric acid, isovaleric acid and 2-methylbutyric acid were significantly reduced (p<0.05); see Figure 2 , the levels of isobutyric acid, butyric acid, valeric acid, and 2-methylbutyric acid in the AD-LET group increased significantly after ET dietary intervention, and the level of isovaleric acid in the AD-LET group showed an increasing trend; similarly, compared with the WT group, the levels of 3-methylvaleric acid and 4-methylvaleric acid in the feces of the AD group mice increased significantly (p<0.05), and these levels decreased significantly after ET dietary intervention (p<0.05); the reasons for the significant differences between different mouse groups were compared, SCFAs in mouse fecal samples were detected, the main SCFAs were analyzed, and the SCFAs content of different mouse groups after ET dietary intervention was compared;

[0057] S32: Identification of volatile organic compounds in mouse feces: Identify volatile organic compounds in mouse feces, select characteristic points and search by GC-IMS, observe GC-IMS spectra, compare and analyze the differences in volatile organic compound concentrations in different groups;

[0058] S33: Correlation analysis was performed between behavioral data of AD mice and fecal volatiles, and the correlation between fecal volatiles and the age of AD mice was analyzed. Changes in metabolic pathways of mice were observed, and the relationship between the age of mice and their total movement distance in the open field movement test, the alternation success rate in the Y maze test, and the exploration time in the novel object recognition test was studied to establish a mouse model of AD disease symptoms.

[0059] S34: Determine candidate molecular markers: select characteristic peak positions of ion mobility spectra in the GC-IMS spectrum, and determine corresponding volatile organic compounds as candidate mouse volatile substance markers;

[0060] S35: Comparison of changes in molecular markers in each group: Draw fingerprints of volatile substances, select volatile organic compounds corresponding to the characteristic peaks of the migration spectrum in the VOC fingerprints, compare the differences in the content of volatile organic compounds between different samples, and explore the reasons for the changes in volatile organic compounds, including 3-Butenenitrile, methyl acetate, 2,3-butanedione-D, 2-ethylfuran-D, 1,2-dimethoxyethane, 2-pentanone-D, butanal-D, 2-pentanone, 2-butanone-D ... The contents of 1-hydroxy-2-propanone-D, 2-methyl-2-propanol, acetic acid, 1-hydroxy-2-propanone, ethylacetate-D, 1-propene-3-methylthio, 1-propanol-D, 2-methyl-2-propenal and other substances were higher in the feces of AD-HET and AD-LET mice, and also higher in the feces of WT mice, which reflects the positive effect of ET intake. The changes of molecular markers in each group were compared, and the comparison samples were screened. See the attachment of the instruction manual. Figure 4 ;

[0061] S36: Comparison of differences and similarities between different markers: Plotting cluster heat maps of mouse fecal samples and analyzing the principal components of mouse fecal samples Cluster analysis of volatile organic compounds was used to visually compare the differences and similarities between different compounds. In the PCoA diagram, the closer the sample points are, the more similar their VOCs compositions are; conversely, the farther the points are from each other, the greater the differences in their compound compositions are. The VOCs composition of WT mice was significantly different from that of AD mice and mice treated with ET. As AD mice age, changes in the composition of VOCs may be related to metabolic changes associated with disease progression, see Figure 5 .

[0062] Example 3

[0063] A volatile biomarker predicting the development of AD in AD-HET mice, key markers include: propyl acetate, 1-penten-3-ol, 2,3-pentanedione, 3-methyl-2-butenal-D;

[0064] The above-mentioned method for screening volatile biomarkers for predicting the development of AD comprises the following steps:

[0065] S1: Feces of AD-HET mice were collected, subjected to low-temperature shaking, crushing, ice bath, ultrasound, mixing and centrifugation, and derivatized with pyridine, EDC solution and 3-NPH for LC-MS / MS analysis.

[0066] S2: Detection of short-chain fatty acids and volatile components in feces of AD-HET mice: GC-IMS technology was used to measure the volatile organic compounds in mice, and GC-IMS data of volatile components in mouse feces samples were obtained;

[0067] S3: Analyze the GC-IMS data of fecal volatile components to obtain volatile biomarkers, which specifically includes the following processes:

[0068] S31: PCoA analysis of the data in mouse feces was performed, and the distribution of samples from different mouse groups in PCoA showed obvious grouping trends, the reasons for significant differences between different mouse groups were compared, SCFAs in mouse fecal samples were detected, the main SCFAs were analyzed, and the SCFAs content of different mouse groups after ET diet intervention was compared;

[0069] S32: Identify volatile organic compounds in mouse feces, select characteristic points and search by GC-IMS, observe GC-IMS spectra, compare and analyze the differences in volatile organic compound concentrations in different groups;

[0070] S33: Correlation analysis was performed between behavioral data of AD mice and fecal volatiles, and the correlation between fecal volatiles and the age of AD mice was analyzed. Changes in metabolic pathways of mice were observed, and the relationship between the age of mice and their total movement distance in the open field movement test, the alternation success rate in the Y maze test, and the exploration time in the novel object recognition test was studied to establish a mouse model of AD disease symptoms.

[0071] S34: selecting characteristic peak positions of ion mobility spectra in the GC-IMS spectrum, and determining corresponding volatile organic compounds as candidate mouse volatile substance markers, and obtaining Table 5;

[0072] S35: Comparison of changes in molecular markers in each group: Draw fingerprints of volatile substances, 3-Butenenitrile, methylacetate, 2,3-butanedione-D, 2-ethylfuran-D, 1,2-dimethoxyethane, 2-pentanone-D, butanal-D, 2-pentanone, 2-butanone-D, 2-methyl-2-propane The contents of 2-methyl-2-propanol, acetic acid, 1-hydroxy-2-propanone, ethylacetate-D, 1-propene-3-methylthio, 1-propanol-D, 2-methyl-2-propenal and other substances were higher in the feces of AD-HET and AD-LET mice, and also higher in the feces of WT mice, which reflects the positive effect of ET intake. In the VOC fingerprint spectrum, the volatile organic compounds corresponding to the characteristic peaks of the migration spectrum were selected, and the differences in the content of volatile organic compounds between different samples were compared to explore the reasons for the changes in volatile organic compounds, compare the changes in molecular markers in each group, and screen the comparison samples. See the attached Figure 4 ;

[0073] S36: Comparison of differences and similarities between different markers: Plotting cluster heat maps of mouse fecal samples, and analyzing the principal components of mouse fecal samples. Cluster analysis of volatile organic compounds was used to visually compare the differences and similarities between different compounds. The composition of VOCs in the feces of 3-month-old AD mice after 6-month intervention with 40 mg / kg ET diet was similar and clustered together. Substances such as propyl acetate, 1-penten-3-ol, and 2,3-pentanedione were initially high in the feces of 3-month-old AD mice; substances such as 3-methyl-2-butenal-D, hexanal-D, and 2-ethoxyethanol were high in the feces of 9-month-old AD mice, see Appendix. Figure 5 In the PCoA diagram, the closer the sample points are, the more similar their VOCs compositions are; on the contrary, the farther the points are, the greater the differences in their compound compositions are. The VOCs composition of WT mice is significantly different from that of AD mice and mice treated with ET. As AD mice age, the changes in VOCs composition may be related to metabolic changes associated with disease progression, see Appendix. Figure 5 .

[0074] Table 5 Information of volatile components detected in mouse fecal samples.

[0075]

[0076]

[0077] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. A volatile biomarker for predicting the development of AD, characterized in that: Including one or more of 3-methylvaleric acid, 4-methylvaleric acid, propyl acetate, 1-penten-3-ol, 2,3-pentanedione, 3-methyl-2-butenal-D, hexanal-D, 2-ethoxyethanol, hexanal, 1-butanol, 2-methylbutanal, ethyl acetate and 2-acetone, propionic acid, isobutyric acid, butyric acid, valeric acid and isovaleric acid.

2. A volatile biomarker for predicting the development of AD according to claim 1, characterized in that: Includes 3-methylvaleric acid, 4-methylvaleric acid, propyl acetate-D and propyl acetate.

3. A volatile biomarker for predicting the development of AD according to claim 1, characterized in that: Includes isobutyric acid, butyric acid, valeric acid and 2-methylbutyric acid.

4. A volatile biomarker for predicting the development of AD according to claim 1, characterized in that: Including propyl acetate, 1-penten-3-ol, 2,3-pentanedione, and 3-methyl-2-butenal-D.

5. The method for determining a combination of volatile biomarkers for predicting the development of AD according to any one of claims 1 to 4, characterized in that: The following steps are involved: The mice were intervened with ergothioneine diet to obtain different mouse groups. The feces of the different mouse groups were tested for short-chain fatty acids and volatile components using the GC-IMS test method to obtain the GC-IMS data of volatile components in the feces of the different mouse groups. The GC-IMS data of fecal volatile components were analyzed to obtain volatile biomarkers.

6. The method for screening volatile biomarkers for predicting the development of AD according to claim 5, characterized in that: The analysis of the GC-IMS data of fecal volatile components includes the following steps: S1: Collect behavioral data of mice in different groups, and perform correlation analysis between behavioral data of mice in different groups and GC-IMS data of fecal volatile components, establish a mouse model of AD disease symptoms, and obtain volatile biomarkers that are positively correlated with the behavioral data of AD group mice through the mouse model of AD disease symptoms; S2: Select the characteristic peak position points of the ion mobility spectrum in the spectrum of the GC-IMS data, and determine the corresponding volatile organic compounds as candidate volatile biomarkers; S3: Draw the fingerprint spectrum of volatile organic compounds, compare the differences and changes of volatile organic compounds between different groups of mice based on the fingerprint spectrum, and screen and determine the volatile organic compounds; S4: Draw a cluster heat map of the feces of different groups of mice, analyze the principal components of the feces of different groups of mice, obtain different clustering situations of volatile biomarkers with positive correlation and volatile organic compounds determined by screening, and perform difference and similarity analysis of volatile biomarkers based on the clustering situation.

7. The method for screening volatile biomarkers for predicting the development of AD according to claim 5, characterized in that: The types of the different groups of mice include AD group mice, AD-LET group mice, AD-HET group mice or C57BL / 6 group mice.

8. The method for screening volatile biomarkers for predicting the development of AD according to claim 5, characterized in that: The behavioral data included the total distance traveled in the open field movement test, the alternation success rate in the Y-maze test, and the exploration time in the novel object recognition test.

9. The method for screening volatile biomarkers for predicting the development of AD according to claim 5, characterized in that: The process of establishing the mouse model of AD disease symptoms specifically includes the following steps: Behavioral data of mice in different groups were collected, the correlation between volatile biomarkers in feces and the age of mice in different groups was analyzed, the changes in metabolic pathways of mice in different groups were observed, and the relationship between the age of mice in different groups and their total movement distance in the open field movement test, the alternation success rate in the Y maze test, and the exploration time in the novel object recognition test was studied to establish a mouse model of AD disease symptoms.

10. Use of a volatile biomarker combination for predicting the development of AD as claimed in any one of claims 1 to 4 in predicting the development of AD.

Citation Information

Patent Citations

  • Alzheimer's disease excrement metabolism marker as well as screening method and application thereof

    CN115754260A

  • Alzheimer's disease biomarker and screening method and application thereof

    CN115774059A

  • Diagnostic tools for alzheimer's disease

    US20160195547A1

  • Biomarkers and uses thereof for diagnosing the silent phase of alzheimer's disease

    US20210325409A1

  • Feces-based biomarker of alzheimer's disease and use thereof

    WO2023206739A1